At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC
In Brief
A Phase 2 clinical trial evaluating Enzalutamide, Laboratory Biomarker Analysis, and 1 other intervention for Castration-Resistant Prostate Carcinoma and 4 related conditions. Active but no longer recruiting, targeting 58 participants across 1 site.
Detailed Summary
This phase II trial studies how well pembrolizumab works in treating patients with prostate cancer that has spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels despite previous treatment with enzalutamide. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Given IV